BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 25605852)

  • 1. Precision immunology: the promise of immunotherapy for the treatment of cancer.
    Kaufman HL
    J Clin Oncol; 2015 Apr; 33(12):1315-7. PubMed ID: 25605852
    [No Abstract]   [Full Text] [Related]  

  • 2. Pancreatic cancer: vaccine is safe and improves survival.
    Hutchinson L
    Nat Rev Clin Oncol; 2015 Mar; 12(3):128. PubMed ID: 25645600
    [No Abstract]   [Full Text] [Related]  

  • 3. Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer.
    Le DT; Wang-Gillam A; Picozzi V; Greten TF; Crocenzi T; Springett G; Morse M; Zeh H; Cohen D; Fine RL; Onners B; Uram JN; Laheru DA; Lutz ER; Solt S; Murphy AL; Skoble J; Lemmens E; Grous J; Dubensky T; Brockstedt DG; Jaffee EM
    J Clin Oncol; 2015 Apr; 33(12):1325-33. PubMed ID: 25584002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cracking the stone: combination vaccination and CTLA-4 blockade in pancreatic cancer.
    Bajor DL; Vonderheide RH
    J Immunother; 2013 Sep; 36(7):362-4. PubMed ID: 23924787
    [No Abstract]   [Full Text] [Related]  

  • 5. Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer.
    Tsujikawa T; Crocenzi T; Durham JN; Sugar EA; Wu AA; Onners B; Nauroth JM; Anders RA; Fertig EJ; Laheru DA; Reiss K; Vonderheide RH; Ko AH; Tempero MA; Fisher GA; Considine M; Danilova L; Brockstedt DG; Coussens LM; Jaffee EM; Le DT
    Clin Cancer Res; 2020 Jul; 26(14):3578-3588. PubMed ID: 32273276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trials of vaccines for pancreatic ductal adenocarcinoma: Is there any hope of an improved prognosis?
    Mizuguchi T; Torigoe T; Satomi F; Shima H; Kutomi G; Ota S; Ishii M; Hayashi H; Asakura S; Hirohashi Y; Meguro M; Kimura Y; Nishidate T; Okita K; Ishino M; Miyamoto A; Hatakenaka M; Sato N; Hirata K
    Surg Today; 2016 Feb; 46(2):139-48. PubMed ID: 25649538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel pancreatic cancer vaccines could unleash the army within.
    Springett GM
    Cancer Control; 2014 Jul; 21(3):242-6. PubMed ID: 24955709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rational combinations of immunotherapy for pancreatic ductal adenocarcinoma.
    Blair AB; Zheng L
    Chin Clin Oncol; 2017 Jun; 6(3):31. PubMed ID: 28705008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Advances in immunotherapy of pancreatic ductal adenocarcinoma].
    Yang JQ; Wei T; Chen YW; Bai XL; Liang TB
    Zhonghua Wai Ke Za Zhi; 2017 May; 55(5):396-400. PubMed ID: 28464583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination for Pancreatic Ductal Adenocarcinoma: A Hard Nut to Crack.
    Salas-Benito D; Melero I; Ponz-Sarvise M
    Clin Cancer Res; 2019 Sep; 25(18):5435-5437. PubMed ID: 31315885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T cell optimization for the treatment of pancreatic cancer.
    Liu F; Saif MW
    Expert Opin Biol Ther; 2017 Dec; 17(12):1493-1501. PubMed ID: 28835191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current advances in immunotherapy for pancreatic cancer.
    Uram JN; Le DT
    Curr Probl Cancer; 2013; 37(5):273-9. PubMed ID: 24331182
    [No Abstract]   [Full Text] [Related]  

  • 13. A practical approach to pancreatic cancer immunotherapy using resected tumor lysate vaccines processed to express α-gal epitopes.
    Furukawa K; Tanemura M; Miyoshi E; Eguchi H; Nagano H; Matsunami K; Nagaoka S; Yamada D; Asaoka T; Noda T; Wada H; Kawamoto K; Goto K; Taniyama K; Mori M; Doki Y
    PLoS One; 2017; 12(10):e0184901. PubMed ID: 29077749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Bacterial-Based Immunotherapy for PDAC.
    Cancer Discov; 2022 Jun; 12(6):OF1. PubMed ID: 35394498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of γδ T cells in pancreatic cancer: what could this mean for the clinic?
    Daley D; Miller G
    Expert Rev Gastroenterol Hepatol; 2017 Jul; 11(7):609-610. PubMed ID: 28345379
    [No Abstract]   [Full Text] [Related]  

  • 16. Q&A: Evidence presenter. Interview by Marian Turner.
    Palucka K
    Nature; 2013 Dec; 504(7480):S9. PubMed ID: 24352364
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment of Locally Advanced Pancreatic Ductal Adenocarcinoma.
    Loehrer AP; Kinnier CV; Ferrone CR
    Adv Surg; 2016 Sep; 50(1):115-28. PubMed ID: 27520867
    [No Abstract]   [Full Text] [Related]  

  • 18. Cancer immunotherapy for pancreatic cancer utilizing α-gal epitope/natural anti-Gal antibody reaction.
    Tanemura M; Miyoshi E; Nagano H; Eguchi H; Matsunami K; Taniyama K; Hatanaka N; Akamatsu H; Mori M; Doki Y
    World J Gastroenterol; 2015 Oct; 21(40):11396-410. PubMed ID: 26523105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant therapy for pancreatic cancer.
    Kleeff J; Friess H; Büchler MW
    Br J Surg; 2007 Mar; 94(3):261-2. PubMed ID: 17315287
    [No Abstract]   [Full Text] [Related]  

  • 20. Pancreatic ductal carcinoma: from the bench to the bedside.
    Pezzilli R
    JOP; 2006 Sep; 7(5):508-10. PubMed ID: 16998251
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.